Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Caprion Proteomics, a provider of proteomics based services to the pharmaceutical industry, has received a $12.9 million contract form the National Institute of Allergy and Infectious Diseases, a part of the US National Institutes of Health, to carry out biodefense research in the area of infectious disease biomarkers.
Subscribe to our email newsletter
Under the contract to be performed over a five-year period, Caprion will act as one of two National Institute of Allergy and Infectious Diseases (NIAID) Clinical Proteomics Centers for Infectious Disease & Biodefense, and will employ its distinctive CellCarta quantitative protein profiling technologies to perform several large scale applied proteomics projects using human clinical samples from patients with infectious diseases.
The projects will be aimed at the discovery, qualification, and verification of candidate biomarkers with potential for clinical use to improve detection and diagnosis and to monitor therapeutic and vaccine responses and susceptibility to infection for diseases caused by various pathogens.
This second major biodefense research contract awarded to Caprion by NIAID builds on the expertise and results demonstrated by Caprion as part of an initial contract awarded in 2004 and still in progress. Caprion will retain rights to commercialize candidate biomarkers and diagnostic products discovered in this project.
Martin LeBlanc, president and CEO of Caprion, said: “This second major contract award from the NIAID provides further evidence of Caprion’s solid scientific capabilities and industry leadership position as a proteomics and biomarker services provider.”